Form 4: Heron Therapeutics Executive Ira Duarte Reports Stock Option and Restricted Stock Unit Grants
SEC Form 4 Filing
EVP and CFO of Heron Therapeutics, Ira Duarte, reports the acquisition of stock options and restricted stock units.
Summary
- Ira Duarte, the Executive Vice President and Chief Financial Officer of Heron Therapeutics, Inc., filed a Form 4 on February 4, 2025.
- The filing reports the grant of employee stock options to purchase 374,220 shares of common stock at an exercise price of $1.70, vesting monthly over 48 months starting February 2025 and expiring January 31, 2035.
- Additionally, Duarte received 187,110 restricted stock units (RSUs) that vest in 16 equal quarterly installments beginning one quarter after January 31, 2025.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The grants themselves are a positive sign of incentivizing management, but the filing is simply a procedural disclosure.
Positives
- The grant of stock options and RSUs to a key executive like the CFO can be seen as an incentive to align their interests with the long-term success of the company.
Future Outlook
The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of future value creation.
Industry Context
Stock options and RSUs are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.
Comparison to Industry Standards
- Executive compensation packages, including stock options and RSUs, are standard practice in the pharmaceutical and biotechnology industries.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based compensation to incentivize their executives.
- The vesting schedules (monthly for options, quarterly for RSUs) are fairly typical, aligning with industry norms for long-term incentive plans.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
- Employees may see the grants as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 01/31/2025 | Date of earliest transaction (grant date of stock options and RSUs) |
| 02/04/2025 | Date of Form 4 filing |
| 01/31/2035 | Expiration date of the stock options |
Keywords
Form 4, insider trading, stock options, restricted stock units, Heron Therapeutics, HRTX, Ira Duarte, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.